Acotec Scientific Holdings Limited (HK:6669)
:6669
Want to see HK:6669 full AI Analyst Report?
6669 Stock Chart & Stats
HK$14.16
-HK$0.14(-2.42%)
At close: 4:00 PM EST
HK$14.16
-HK$0.14(-2.42%)
Day’s Range― - ―
52-Week RangeHK$7.07 - HK$15.47
Previous CloseN/A
Volume343.13K
Average Volume (3M)462.19K
Market Cap
HK$2.57B
Enterprise ValueHK$2.02B
Total Cash (Recent Filing)HK$995.38M
Total Debt (Recent Filing)HK$236.13M
Price to Earnings (P/E)18.6
Beta1.07
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.34
Shares Outstanding313,389,160
10 Day Avg. Volume400,669
30 Day Avg. Volume462,190
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.51
Price to Sales (P/S)5.75
P/FCF Ratio25.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$17.00Price Target Upside20.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.45
Revenue Forecast (FY)HK$732.25M
Bulls Say, Bears Say
Bulls Say
High Gross And Improving Net MarginsSustained very high gross margin (~72%) and a marked net margin improvement to ~18.5% imply durable product-level profitability and pricing power in interventional devices. This supports reinvestment for R&D and commercialization, and helps sustain cash generation even if procedure volumes fluctuate.
Strengthening Cash GenerationMaterial improvement in operating and free cash flow (OCF 167M, FCF 145M) increases financial flexibility for capex, working capital and product commercialization. Strong cash conversion reduces reliance on external funding and supports longer-term investment in hospital coverage and physician adoption.
Conservative Leverage And Repaired Balance SheetLow leverage and a repaired equity base provide headroom to invest, absorb shocks and pursue strategic initiatives. A conservative capital structure lowers refinancing risk through cycles and supports measured M&A or commercial expansion without jeopardizing liquidity or credit standing.
Bears Say
Historical Earnings And Cash VolatilityPrior periods of losses and inconsistent operating cash flow indicate earnings volatility and sensitivity to demand or execution. That history raises uncertainty about sustainability of margins and cash conversion through downturns, complicating long-term forecasting and capital allocation.
Moderate Returns On EquityROE at ~7.9% suggests only moderate efficiency in converting equity into profit. Over time this can limit shareholder returns and signal either pricing/competitive pressure or heavy reinvestment needs; it may also constrain ability to rapidly scale returns relative to higher‑return competitors.
Modest And Uneven Revenue GrowthRelatively modest top-line growth limits the pace at which operating leverage and scale can compound. Dependence on hospital adoption and procedure volumes means sustained above‑trend growth requires expanding coverage and clinician uptake; failure to do so could constrain margin expansion.
Acotec Scientific Holdings Limited News
6669 FAQ
What was Acotec Scientific Holdings Limited’s price range in the past 12 months?
Acotec Scientific Holdings Limited lowest stock price was HK$7.07 and its highest was HK$15.47 in the past 12 months.
What is Acotec Scientific Holdings Limited’s market cap?
Acotec Scientific Holdings Limited’s market cap is HK$2.57B.
When is Acotec Scientific Holdings Limited’s upcoming earnings report date?
Acotec Scientific Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 77 days.
How were Acotec Scientific Holdings Limited’s earnings last quarter?
Acotec Scientific Holdings Limited released its earnings results on Mar 26, 2026. The company reported HK$0.112 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.112.
Is Acotec Scientific Holdings Limited overvalued?
According to Wall Street analysts Acotec Scientific Holdings Limited’s price is currently Undervalued.
Does Acotec Scientific Holdings Limited pay dividends?
Acotec Scientific Holdings Limited does not currently pay dividends.
What is Acotec Scientific Holdings Limited’s EPS estimate?
Acotec Scientific Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acotec Scientific Holdings Limited have?
Acotec Scientific Holdings Limited has 313,389,160 shares outstanding.
What happened to Acotec Scientific Holdings Limited’s price movement after its last earnings report?
Acotec Scientific Holdings Limited reported an EPS of HK$0.112 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.51%.
Which hedge fund is a major shareholder of Acotec Scientific Holdings Limited?
Currently, no hedge funds are holding shares in HK:6669
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.
6669 Stock 12 Month Forecast
Average Price Target
HK$17.00
▲(20.06% Upside)
Technical Analysis
Peijia Medical Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―
Options Prices
Currently, No data available
---